2015
DOI: 10.1016/j.brainres.2015.10.027
|View full text |Cite
|
Sign up to set email alerts
|

Nesfatin-1, a potent anorexic agent, decreases exploration and induces anxiety-like behavior in rats without altering learning or memory

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
26
0
1

Year Published

2017
2017
2022
2022

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 44 publications
(29 citation statements)
references
References 55 publications
2
26
0
1
Order By: Relevance
“…Considering the increased plasma nesfatin‐1 levels in patients with impaired glucose tolerance and newly diagnosed T2DM, hyperglycaemia and hyperlipidaemia in NAFLD might also contribute to the increased nesfatin‐1 abundance. Moreover, the results of our previous studies have suggested an association between nesfatin‐1 and the hypothalamic‐pituitary‐adrenal axis . In NAFLD rats, the plasma corticosterone concentration was increased (66.25±2.51 nmol/L vs 51.13±4.25 nmol/L; unpublished data), which might be another contributor to the change in plasma nesfatin‐1 levels in NAFLD rats.…”
Section: Discussionmentioning
confidence: 73%
See 1 more Smart Citation
“…Considering the increased plasma nesfatin‐1 levels in patients with impaired glucose tolerance and newly diagnosed T2DM, hyperglycaemia and hyperlipidaemia in NAFLD might also contribute to the increased nesfatin‐1 abundance. Moreover, the results of our previous studies have suggested an association between nesfatin‐1 and the hypothalamic‐pituitary‐adrenal axis . In NAFLD rats, the plasma corticosterone concentration was increased (66.25±2.51 nmol/L vs 51.13±4.25 nmol/L; unpublished data), which might be another contributor to the change in plasma nesfatin‐1 levels in NAFLD rats.…”
Section: Discussionmentioning
confidence: 73%
“…Increased plasma nesfatin‐1 levels have been reported in MDD patients, as associated with elevated scores of anxiety and depression . The results of our previous studies have also demonstrated that chronic administration of nesfatin‐1 could decrease exploration and induce anxiety‐like and depression‐like behaviours in rats . However, little is known about the role of nesfatin‐1 in NAFLD, which presents not only glucose and lipid metabolism disorders, but also neuropsychiatric injuries.…”
Section: Introductionmentioning
confidence: 85%
“…In addition, when animals were exposed to a novel environment, nesfatin-1 not only increased the latency to eat palatable food but also decreased the amount consumed (Merali et al 2008). In an open field test, both an acute central nervous ) and a peripheral chronic administration of nesfatin-1 (Ge et al 2015) increased anxiety-like behavior. The latter was accompanied by reduced brain-derived neurotrophic factor (BDNF) and ERK 1 and 2 phosphorylation in the prefrontal cortex and hippocampus (Ge et al 2015).…”
Section: :1mentioning
confidence: 92%
“…In an open field test, both an acute central nervous ) and a peripheral chronic administration of nesfatin-1 (Ge et al 2015) increased anxiety-like behavior. The latter was accompanied by reduced brain-derived neurotrophic factor (BDNF) and ERK 1 and 2 phosphorylation in the prefrontal cortex and hippocampus (Ge et al 2015). Moreover, nesfatin-1-induced anxiety was blocked by the co-administration of SHU9119 ), indicating that nesfatin-1 participates in stress response mechanisms by recruiting the central melanocortin system.…”
Section: :1mentioning
confidence: 96%
“…Nesfatin-1, another new anorexigenic peptide hormone, plays an important role in the integration of food intake, energy expenditure, and glucose homeostasis (9). In the past decade, nesfatin-1 has been found to be involved in a variety of affective disorders, including anxiety disorder (10), depression (11), and psychosis (12). However, no studies on the relationship between nesfatin-1 in AD and craving have been conducted.…”
Section: Introductionmentioning
confidence: 99%